0000000000609265
AUTHOR
Craig M. Kessler
showing 3 related works from this author
Hemophilia A and Hemophilia B
2019
Abstract While observed for centuries, the diseases that we call hemophilia have been clarified and elucidated in the past 50 to 60 years. We now know the genetics and transmission of the various types of hemophilia and are greatly facilitated by their laboratory features. Various hemorrhagic manifestations of the various hemophilias include hemarthrosis, intramuscular hemorrhage, retroperitoneal bleeding, retropharyngeal bleeding, and central nervous system hemorrhage. In the past, trauma and surgery were associated with serious or fatal bleeding. Now, multiple agents are available to treat or prophylax against hemorrhage. Specific diagnoses require specific therapeutics. Fatal hemorrhagic…
Autoantibody Inhibitor Eradication In Acquired Hemophilia Associated with Cancer: a Retrospective Analysis
2010
Abstract Abstract 1418 Introduction: Acquired hemophilia (AH), a rare autoimmune disorder primarily of adults, is typically characterized by the presence of IgG oligoclonal antibodies to the clotting factor VIII protein (FVIII). About 10–15% of patients with AH have an underlying malignancy, but the etiologic relationship of cancer to formation of FVIII inhibitor is yet to be determined. To date, there have been no published, comprehensive reviews on the efficacy of various treatments for AH in the context of either solid tumor or hematologic malignancies. Therefore, we have systematically reviewed 86 patients with cancer-associated AH from our own cancer center and from the published liter…
Acquired haemophilia in cancer: A systematic and critical literature review
2017
Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…